DCTH

#2769
Delcath Systems Inc
8.9000
-2.41%
版块:
基础:
利润货币:
日范围
8.9000
8.9000
年范围
8.1200
11.1500
日变化
-2.41%
每月变动
-12.92%
6个月变化
-13.93%
年变化
-13.93%
前一天收盘价
9.1200
Open
8.9000
Bid
Ask
Low
8.9000
High
8.9000
交易量
51
Open full chart

Financials

Overview 声明 Statistics Dividends
Quarterly Annual
  • Market Capitalization 323.8112 M
  • Employee 76
  • Founded 1988
  • CEO Gerard Michel
  • Website www.delcath.com
  • Headquarter Delaware, United States
  • FIGI BBG000BY2VF5
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
144.29
Price to sales ratio
—
Dividends per share
—
Dividend yield %
—

Delcath Systems Inc

Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.

新闻